Effects of progesterone on the content of CCR5 and CXCR4 coreceptors in PBMCs of seropositive and exposed but uninfected Mexican women to HIV-1

Cabrera-Muñoz, Edith; Fuentes-Romero, Luis L.; Zamora-Chávez, Jorge; Camacho‐Arroyo, Ignacio; Soto-Ramírez, Luis Enrique

doi:10.1016/j.jsbmb.2012.02.001

Cited by 18 publications

(17 citation statements)

References 41 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro studies on hormone effects support the clinical studies discussed earlier. A study showed progesterone decreased CCR5 expression and increased CXCR4 expression in PBMCs of HIV-uninfected and -infected patient samples cultured with progesterone suggesting progesterone may modulate HIV infection at receptor level (Cabrera-Munoz et al 2012). We also observed in our previous in vitro study that progesterone augments replication and transmission of major HIV-1 subtypes (Ragupathy et al 2013).…”

Section: Introductionsupporting

confidence: 78%

Progesterone augments cell susceptibility to HIV-1 and HIV-1/HSV-2 co-infections

Ragupathy

Wang

Tan

et al. 2016

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

In human immunodeficiency virus type 1 (HIV-1)-infected women, oral or injectable progesterone containing contraceptive pills may enhance HIV-1 acquisition in vivo, and the mechanism by which this occurs is not fully understood. In developing countries, Herpes simplex virus type-2 (HSV-2) co-infection has been shown to be a risk for increase of HIV-1 acquisition and, if co-infected women use progesterone pills, infections may increase several fold. In this study, we used an in vitro cell culture system to study the effects of progesterone on HIV-1 replication and to explore the molecular mechanism of progesterone effects on infected cells. In our in vitro model, CEMss cells (lymphoblastoid cell line) were infected with either HIV-1 alone or co-infected with HSV-2. HIV-1 viral load was measured with and without sex hormone treatment. Progesterone-treated cells showed an increase in HIV-1 viral load (1411.2 pg/mL) compared with cells without progesterone treatment (993.1 pg/mL). Increased cell death was noted with HSV-2 co-infection and in progesterone-treated cells. Similar observations were noted in peripheral blood mononuclear cells (PBMC) cells derived from three female donors. Progesterone-treated cells also showed reduced antiviral efficacy. Inflammatory cytokines and associations with biomarkers of disease progression were explored. Progesterone upregulated inflammatory cytokines and chemokines conversely and downregulated anti-apoptotic Bcl-2 expression. Nuclear protein analysis by electrophoretic mobility shift assay showed the association of progesterone with progesterone response element (PRE), which may lead to downregulation of Bcl-2. These data indicate that progesterone treatment enhances HIV-1 replication in infected cells and co-infection with HSV-2 may further fuel this process.

show abstract

Section: Introductionsupporting

confidence: 78%

Progesterone augments cell susceptibility to HIV-1 and HIV-1/HSV-2 co-infections

Ragupathy

Wang

Tan

et al. 2016

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…This compound strongly binds to the progesterone and glucocorticoid receptors, and to a lesser extent to the androgen receptor, besides, it is known that the modulatory effects of RU486 are complex and depend on species, tissue, dose, and duration of treatment [25,26]. According to the above, it is possible that under the treatment of 1 h, RU486 activates different signaling pathways that finally increase PIBF expression.…”

Section: Discussionmentioning

confidence: 99%

Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway

González-Arenas

Valadez-Cosmes

Jiménez-Arellano

et al. 2014

The Journal of Steroid Biochemistry and Molecular Biology

Self Cite

View full text Add to dashboard Cite

“…Following the 2012 WHO consultation, the global health community responded with new modeling analyses [5][6][7][8], anatomical, microbiological, and immunological data [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24], supplementary epidemiological analyses [25,26], commentaries [27][28][29], overviews and guideline updates based on the systematic reviews [30][31][32][33], technical briefings [34], and analytical recommendations for future observational analyses of HC and HIV acquisition [35]. Conversations continue about the feasibility and scientific benefit of a randomized trial of various HC methods and HIV risk [28,36,37].…”

Section: Introductionmentioning

confidence: 99%

Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence

Polis¹,

Phillips²,

Curtis³

et al. 2014

Contraception

112

View full text Add to dashboard Cite

Whether use of various types of hormonal contraception (HC) affect risk of HIV acquisition is a critical question for women's health. For this systematic review, we identified 22 studies published by January 15, 2014 which met inclusion criteria; we classified thirteen studies as having severe methodological limitations, and nine studies as "informative but with important limitations". Overall, data do not support an association between use of oral contraceptives and increased risk of HIV acquisition. Uncertainty persists regarding whether an association exists between depot-medroxyprogesterone acetate (DMPA) use and risk of HIV acquisition. Most studies suggested no significantly increased HIV risk with norethisterone enanthate (NET-EN) use, but when assessed in the same study, point estimates for NET-EN tended to be larger than for DMPA, though 95% confidence intervals overlapped substantially. No data have suggested significantly increased risk of HIV acquisition with use of implants, though data were limited. No data are available on the relationship between use of contraceptive patches, rings, or hormonal intrauterine devices and risk of HIV acquisition. Women choosing progestin-only injectable contraceptives such as DMPA or NET-EN should be informed of the current uncertainty regarding whether use of these methods increases risk of HIV acquisition, and like all women at risk of HIV, should be empowered to access and use condoms and other HIV preventative measures. Programs, practitioners, and women urgently need guidance on how to maximize health with respect to avoiding both unintended pregnancy and HIV given inconclusive or limited data for certain HC methods.

show abstract

Effects of progesterone on the content of CCR5 and CXCR4 coreceptors in PBMCs of seropositive and exposed but uninfected Mexican women to HIV-1

Cited by 18 publications

References 41 publications

Progesterone augments cell susceptibility to HIV-1 and HIV-1/HSV-2 co-infections

Progesterone augments cell susceptibility to HIV-1 and HIV-1/HSV-2 co-infections

Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway

Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence

Contact Info

Product

Resources

About